PACB Pacific Biosciences of California, Inc. - Common Stock
NASDAQ · Life Sciences Tools & Services · SEC EDGAR'da Görüntüle ↗ kapat Eki 2, 2026 10-K/10-Q Ağu 6, 2026
$2,54
· 52 haftalık aralığın %'i
· düşüğün üstünde
· yükseğe
$1,0752 haftanın en düşüğü
$2,7352 haftanın en yükseği
Piyasa Değeri (MRQ)
$789M
P/E (TTM)
-6.2
Hisse Başına Kâr (TTM)
$-0.41
Gelir (TTM)
$159M
rozetleriniz
52 Haftlık Aralık
$1–$3
Analist Derecelendirmesi
BUY
Fiyat Hedefi
$2
P/E
-6.2
ROE
-929.3%
Net Kâr Marjı
-82.5%
Rozet şeridiniz boş — bu sayfada herhangi bir metriği sabitleyin.
PACB Hisse Senedi Özeti Fiyat, piyasa değeri, P/E, EPS, ROE, borç/öz sermaye, 52 haftalık aralık
Fiyat
$2.54
Piyasa Değeri (MRQ)
$789M
P/E (TTM)
-6.2
Hisse Başına Kâr (TTM)
$-0.41
Gelir (TTM)
$159M
ROE (TTM)
-929.3%
52 Haftlık Aralık
$1–$3
PACB Hisse Senedi Fiyat Grafiği Teknik göstergeler ile günlük OHLCV — kaydır, yakınlaştır ve görünümünüzü özelleştirin
aralık
çubuklar
Çubuk çözünürlüğü seçilen döneme uyum sağlar — bir çubuk için açılış/yüksek/düşük/kapanış değerlerini görmek için grafiğin üzerine gelin.
Pacific Biosciences of California, Inc. - Common Stock Hakkında Wikipedia'dan şirket genel bakışı
Pacific Biosciences of California, Inc. (a.k.a. PacBio) is an American biotechnology company founded in 2004 that develops and manufactures systems for gene sequencing and some novel real time biological observation. PacBio has two principal sequencing platforms: single-molecule real-time sequencing (SMRT), based on the properties of zero-mode waveguides and sequencing by binding (SBB) chemistry, which uses native nucleotides and scarless incorporation for DNA binding and extension.
History
The company was founded based on research done at Cornell University that combined semiconductor processing and photonics with biotechnology research. Three graduate students in the lab of Professors Watt W. Webb — Jonas Korlach — and Harold Craighead — Steve Turner and Mathieu Foquet — became the first employees.
It began under the name Nanofluidics, Inc. The company raised nearly US$400,000,000 in six rounds of primarily venture capital financing, making it one of the most capitalized startups in 2010 leading up to their public offering in October of that year. Key investors included Mohr Davidow Ventures, Kleiner, Perkins, Caufield & Byers, Alloy Ventures, and Wellcome Trust.
The company's first commercial product, the PacBio RS, was sold to a limited set of customers in 2010 and was commercially released in early 2011. A subsequent version of the sequencer called the PacBio RS II was released in April 2013.
Leadership
In 2004, Kleiner Perkins entrepreneur-in-residence Hugh Martin became CEO. On 6 January 2012 board member Michael Hunkapiller, PhD assumed the role of CEO. Hunkapiller retired in September 2020, and was replaced by chairman of the board Christian Henry. Henry was a former executive VP and chief commercial officer of Illumina before joining the board at PacBio in July 2018.
Illumina: attempted acquisition
On 1 November 2018, Illumina, Inc. agreed to purchase PacBio for US$1.2 billion in cash. The deal was expected to close in the fourth quarter of 2019. In December 2019, the Federal Trade Commission sued to block the acquisition. The deal was abandoned with an announcement on 2 January 2020. Illumina further agreed to pay Pacific Biosciences a $98 million US termination fee plus previously agreed upon deal extension payments of $22 million US in February and $6 million US in March 2020.
Sequencing technology
Sequencing instruments
The company's first scientific instrument, called the PacBio RS, was released to a limited set of customers in late 2010., with full commercial release in early 2011. Sequencing provider GATC Biotech was selected by Pacific Biosciences as its first European service provider in late 2010. A new version of the sequencer was released in April 2013 it produced longer sequence reads and higher throughput than the original RS instrument. The RS instrument will officially be supported until the end of 2021. In September 2015, the company released a new sequencing instrument, the Sequel System, with increased sequencing capacity at a smaller size and lower price compared to the PacBio RS II. Subsequently, in October 2022, PacBio launched a new sequencing system, which can sequence 1,300 human genomes per year as compared to 86 per year of the previous PacBio sequencing machines.
Reagents and SMRT Cells
To use either instrument, customers must also purchase reagent packs for DNA preparation and sequencing and small consumables called "SMRT Cells." Cells for early forms of the sequencer are slightly less than one-centimeter square and contains tens of thousands of zero-mode waveguides, whereas newer systems have a higher density of cells and contain 25 million zero-mode waveguides (ZMWGs), allowing for faster DNA sequencing.
Software and applications
Their secondary analysis bioinformatics product for the RS, called “SMRT Analysis”, was open source. For the Sequel system the secondary analysis software was reorganized as the "SMRT Link" application. In 2013, the company released new bioinformatics tools for automated genome assembly (HGAP) and finishing (Quiver).
Kaynak: Wikipedia (İngilizce), CC BY-SA 4.0 · Wikipedia'da Görüntüle ↗
sektörHealthcare
endüstriLife Sciences Tools & Services
çalışanlar485
ülkeUS
10 Yıllık Performans Gelir, net kar, marjlar ve EPS trendleri
Gelir$160M2016-12-31 → 2025-12-31
Hisse Başına Kâr$-1.822018-12-31 → 2025-12-31
Serbest Nakit Akışı$-114M2016-12-31 → 2025-12-31
Net kar marjı-82.5%2016-12-31 → 2025-12-31
Değerleme ve Oranlar
Değerleme P/E, P/S, P/B, EV/EBITDA oranları — hisse senedi pahalı mı ucuz mu?
| Metrik | 5 Yıllık trend | PACB | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| P/E (TTM) | -6.25Y ort. ≈-7.8 | ≈-7.8 | · | · | |
| F/S (TTM) | 5.05Y ort. ≈13.8 | ≈13.8 | 4.6 | Düşük değerli | |
| F/D (MRQ) | -23.85Y ort. ≈23.9 | ≈23.9 | · | · | |
| Fiyat / Serbest Nakit Akışı (TTM) | -6.45Y ort. ≈-12.5 | ≈-12.5 | · | · | |
| Fiyat / Nakit Akışı (TTM) | -6.75Y ort. ≈-13.1 | ≈-13.1 | · | · | |
| Fiyat / Maddi Defter Değeri (MRQ) | -17.1 | · | · | · |
Akran ortalaması, metrik başına standartlaştırılmış bir temelde hesaplanır ve bu hisse senedi için gösterilen TTM/MRQ temelini her zaman eşleşmeyebilir.
Kârlılık Brüt, faaliyet ve net kâr marjları; ROE, ROA, ROIC
| Metrik | 5 Yıllık trend | PACB | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Brüt Kar Marjı (TTM) | 36.4%5Y ort. ≈32.5% | ≈32.5% | 46.6% | Zayıf | |
| Faaliyet Kâr Marjı (TTM) | -83.5%5Y ort. ≈-244.3% | ≈-244.3% | -22.1% | Zayıf | |
| EBITDA Margin (FAVÖK Marjı) | -346.1%5Y ort. ≈-244.3% | ≈-244.3% | -22.1% | Zayıf | |
| Vergi Öncesi Kar Marjı (TTM) | -82.0%5Y ort. ≈-231.3% | ≈-231.3% | -15.3% | Zayıf | |
| Net Kâr Marjı (TTM) | -82.5%5Y ort. ≈-215.9% | ≈-215.9% | -21.1% | Zayıf | |
| ROA (TTM) | -16.7%5Y ort. ≈-24.6% | ≈-24.6% | -8.3% | Zayıf | |
| ROE (TTM) | -929.3%5Y ort. ≈-363.3% | ≈-363.3% | -10.9% | Zayıf | |
| ROIC | -10360.5%5Y ort. ≈-2629.4% | ≈-2629.4% | -16.2% | Zayıf |
Finansal Sağlık Borç, likidite, solventlik — bilanço gücü
| Metrik | 5 Yıllık trend | PACB | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Cari Oran (MRQ) | 4.95Y ort. ≈7.8 | ≈7.8 | 4.5 | Güçlü likidite | |
| Cari Oran (MRQ) | 3.95Y ort. ≈7.1 | ≈7.1 | 1.7 | Güçlü likidite |
Büyüme Gelir, EPS ve net gelir büyümesi: YOY, 3 Yıllık CAGR, 5 Yıllık CAGR
| Metrik | 5 Yıllık trend | PACB | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Revenue YoY (Gelir Yıllık Bazda) | 3.9%5Y ort. ≈20.1% | ≈20.1% | · | · | |
| Revenue CAGR 3Y (Gelir 3 Yıllık Bileşik Büyüme Oranı) | 7.6%5Y ort. ≈16.6% | ≈16.6% | · | · | |
| Revenue CAGR 5Y (Gelir 5 Yıllık Bileşik Büyüme Oranı) | 15.2% | · | · | · |
Sermaye Verimliliği Aktif devir hızı, stok devir hızı, alacak devir hızı
| Metrik | 5 Yıllık trend | PACB | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Asset Turnover (Aktif Devir Hızı) | 0.25Y ort. ≈0.1 | ≈0.1 | 0.3 | Zayıf | |
| Inventory Turnover (Stok Devir Hızı) | 2.15Y ort. ≈2.5 | ≈2.5 | 3.5 | Zayıf | |
| Receivables Turnover (Alacak Devir Hızı) | 5.15Y ort. ≈5.9 | ≈5.9 | 5.8 | Zayıf | |
| Revenue / Employee (Çalışan Başına Gelir) | ≈$329.9K | · | · | · |
değer · ≈ 5Y ort. · sektör ortalaması · ortalamaya göre değerlendirme
Kazanç Geçmişi EPS gerçekleşen vs tahmin, sürpriz %, kazanma oranı, bir sonraki kazanç tarihi
Ort. Sürpriz
-97.7%
Sonraki Rapor
Kas 03, 2026
| Dönem | Rapor | EPS Gerçek | EPS Tahmin | Sürpriz |
|---|---|---|---|---|
| 30 Haziran 2026 | Ağu 3, 2026 | $-0.14 | $-0.13 | -7.9% |
| 31 Mart 2026 | $-0.12 | $-0.14 | 12.7% | |
| 31 Aralık 2025 | $-0.12 | $-0.15 | 20.3% | |
| 30 Eylül 2025 | $-0.13 | $-0.15 | 16.1% | |
| 30 Haziran 2025 | $-0.14 | $-0.17 | 19.3% | |
| 31 Mart 2025 | $-1.44 | $-0.19 | -646.9% |
Tüm Temeller Tüm metrikler yıla göre — gelir tablosu, bilanço, nakit akışı
Gelir Tablosu
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $160M | $154M | $201M | $128M | $131M | $79M | $91M | $79M | $93M | $91M | $93M | $61M | |
| Cost of Revenue | $114M | $117M | $148M | $79M | $72M | $46M | $56M | $54M | $59M | $47M | $39M | $37M | |
| Gross Profit | $46M | $37M | $53M | $49M | $59M | $33M | $35M | $25M | $35M | $44M | $53M | $23M | |
| R&D Expense | $97M | $135M | $187M | $193M | $113M | $64M | $60M | $63M | $65M | $68M | $60M | $48M | |
| SG&A Expense | $141M | $175M | $170M | $161M | $124M | $73M | $75M | $63M | $59M | $48M | $45M | $38M | |
| Operating Expenses | $600M | $512M | $387M | $356M | $269M | $137M | $135M | $126M | $124M | $115M | $83M | $86M | |
| Operating Income | $-554M | $-474M | $-334M | $-307M | $-210M | $-104M | $-101M | $-101M | $-90M | $-71M | $-29M | $-63M | |
| Interest Expense | · | · | $14M | $15M | $13M | $267.0K | $3M | $2M | $3M | $3M | $3M | $3M | |
| Other Non-op | $15M | $24M | $33M | $8M | $93.0K | $2M | $1M | $848.0K | $516.0K | $103.0K | $364.0K | $-478.0K | |
| Pretax Income | $-546M | $-310M | $-318M | $-314M | $-275M | $29M | $-84M | · | · | · | · | · | |
| Income Tax | $318.0K | $316.0K | $-11M | $0 | $-94M | · | · | · | · | · | · | · | |
| Net Income | $-546M | $-310M | $-307M | $-314M | $-181M | $29M | $-84M | $-103M | $-92M | $-74M | $-32M | $-66M | |
| EPS (Basic) | $-1.82 | $-1.13 | $-1.21 | $-1.40 | $-0.89 | $0.18 | $-0.55 | $-0.76 | · | · | · | · | |
| EPS (Diluted) | $-1.82 | $-1.59 | $-1.21 | $-1.40 | $-0.89 | $0.17 | $-0.55 | $-0.76 | · | · | · | · | |
| Shares (Basic) | 299,959,000 | 274,488,000 | 253,629,000 | 224,550,000 | 204,136,000 | 165,187,000 | 152,527,000 | 135,094,000 | · | · | · | · | |
| Shares (Diluted) | 299,959,000 | 288,366,000 | 253,629,000 | 224,550,000 | 204,136,000 | 174,970,000 | 152,527,000 | 135,094,000 | · | · | · | · | |
| EBITDA | $-554M | $-474M | $-334M | $-307M | $-210M | $-104M | $-101M | $-94M | $-81M | $-67M | $-25M | $-59M |
Bilanço
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $64M | $55M | $180M | $325M | $461M | $82M | $30M | $19M | $17M | $17M | $34M | $36M | |
| Short-term Investments | $216M | $335M | $452M | $447M | $584M | $237M | $19M | $84M | $46M | $55M | $49M | $65M | |
| Receivables | $35M | $28M | $37M | $19M | $24M | $17M | $15M | $9M | $13M | $11M | $5M | $3M | |
| Inventory | $49M | $59M | $57M | $50M | $25M | $14M | $13M | $18M | $23M | $16M | $11M | $11M | |
| Prepaid Expense | $11M | $19M | $17M | $10M | $7M | $5M | $3M | $3M | $2M | $10M | $12M | $2M | |
| Other Current Assets | · | · | · | · | · | · | · | · | $931.0K | $476.0K | $741.0K | $107.0K | |
| Current Assets | $375M | $496M | $742M | $852M | $1.10B | $356M | $81M | $132M | $102M | $109M | $111M | $118M | |
| PP&E (Net) | $24M | $31M | $36M | $42M | $33M | $25M | $30M | $34M | $38M | $15M | $9M | $7M | |
| PP&E (Gross) | $117M | $112M | $111M | $107M | $89M | $75M | $74M | $71M | $70M | $52M | $42M | $37M | |
| Accum. Depreciation | $92M | $82M | $75M | $65M | $56M | $50M | $44M | $37M | $32M | $37M | $34M | $30M | |
| Goodwill | $318M | $318M | $462M | $410M | $410M | · | · | · | · | · | · | · | |
| Intangibles | $15M | $390M | $457M | $410M | $411M | · | · | · | · | · | · | · | |
| Other Non-current Assets | $9M | $9M | $13M | $11M | $1M | $43.0K | $42.0K | $43.0K | $45.0K | $10M | $8M | $29.0K | |
| Total Assets | $784M | $1.26B | $1.75B | $1.77B | $2.01B | $414M | $148M | $170M | $144M | $138M | $131M | $124M | |
| Accounts Payable | $21M | $17M | $15M | $12M | $11M | $4M | $8M | $7M | $9M | $8M | $5M | $6M | |
| Accrued Liabilities | $34M | $23M | $46M | $33M | $36M | $17M | $13M | $13M | $13M | $17M | $16M | $11M | |
| Short-term Debt | · | $0 | $490.0K | $2M | $2M | · | $16M | · | · | · | · | · | |
| Current Liabilities | $73M | $66M | $95M | $263M | $72M | $39M | $49M | $27M | $29M | $34M | $38M | $31M | |
| Capital Leases | $57M | $15M | $32M | $41M | $50M | $38M | $42M | · | · | · | · | $2M | |
| Other Non-current Liabilities | $0 | $546.0K | $751.0K | $1M | $3M | $752.0K | · | · | · | $2M | $1M | $2M | |
| Total Liabilities | $779M | $754M | $1.04B | $1.20B | $1.22B | $78M | $93M | $56M | $58M | $53M | $58M | $69M | |
| Long-term Debt | · | · | · | $897M | $896M | · | $16M | $15M | $14M | $16M | · | $14M | |
| Total Debt | · | $0 | $490.0K | $2M | $2M | · | $16M | · | · | · | · | · | |
| Common Stock | $302.0K | $294.0K | $268.0K | $227.0K | $221.0K | $192.0K | $153.0K | $150.0K | $116.0K | $93.0K | $80.0K | $74.0K | |
| Paid-in Capital | $2.70B | $2.65B | $2.54B | $2.10B | $2.01B | $1.37B | $1.12B | $1.10B | $966M | $872M | $787M | $736M | |
| Retained Earnings | $-2.70B | $-2.15B | $-1.84B | $-1.53B | $-1.22B | $-1.04B | $-1.07B | $-982M | $-880M | $-788M | $-713M | $-681M | |
| AOCI | $457.0K | $422.0K | $219.0K | $-5M | $-1M | $85.0K | $5.0K | $-36.0K | $-32.0K | $5.0K | $-7.0K | $9.0K | |
| Stockholders' Equity | $5M | $507M | $701M | $563M | $791M | $335M | $55M | $114M | $86M | $85M | $74M | $55M | |
| Liabilities + Equity | $784M | $1.26B | $1.75B | $1.77B | $2.01B | $414M | $148M | $170M | $144M | $138M | $131M | $124M | |
| Shares Outstanding | 301,956,000 | 294,418,000 | 267,744,000 | 226,505,000 | 220,978,000 | 192,294,000 | 153,119,000 | 150,244,000 | 116,277,000 | 92,677,000 | 79,983,000 | 73,927,000 |
Nakit Akışı
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | · | · | · | · | · | · | · | $7M | $8M | $4M | $4M | $4M | |
| Stock-based Comp | $42M | $71M | $72M | $79M | $73M | $18M | $16M | $23M | $20M | $20M | $14M | $10M | |
| Deferred Tax | $-546.0K | $-205.0K | $-11M | $0 | $-94M | · | · | · | · | · | · | · | |
| Amort. of Intangibles | $369M | $27M | $8M | $913.0K | $0 | $0 | $0 | · | · | · | · | · | |
| Restructuring | · | $13M | · | · | · | · | · | · | · | · | · | · | |
| Other Non-cash | · | · | · | · | · | · | · | $6M | $-4M | $-17M | $-34M | $528.0K | |
| Operating Cash Flow | $-111M | $-206M | $-259M | $-263M | $-111M | $20M | $-78M | $-66M | $-68M | $-68M | $-48M | $-51M | |
| CapEx | $3M | $6M | $9M | $17M | $6M | $1M | $3M | $2M | $10M | $8M | $3M | $2M | |
| Investing Cash Flow | $115M | $124M | $5M | $116M | $-679M | $-219M | $62M | $-38M | $-2M | $-15M | · | · | |
| Stock Issued | $0 | $0 | $189M | $0 | $32M | $46M | $9M | $10M | $9M | $8M | $7M | $4M | |
| Net Stock Activity | $0 | $0 | $15M | $11M | $32M | $46M | $9M | $10M | $9M | $8M | $7M | $4M | |
| Financing Cash Flow | $3M | $-43M | $109M | $10M | $1.17B | $252M | $27M | $107M | $69M | $66M | · | · | |
| Net Change in Cash | $8M | $-125M | $-146M | $-138M | $380M | · | · | · | $-258.0K | $-17M | $-3M | $10M | |
| Taxes Paid | $481.0K | $256.0K | $140.0K | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | $-114M | $-212M | $-268M | $-280M | $-117M | $18M | $-81M | $-68M | $-78M | $-76M | $-51M | $-53M | |
| Levered FCF | · | · | $-282M | · | $-125M | · | · | · | · | · | · | · |
Kârlılık
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 28.6% | 24.2% | 26.3% | 38.2% | 45.1% | 41.3% | 38.0% | 31.9% | 37.1% | 48.7% | 57.6% | 38.6% | |
| Operating Margin | -346.1% | -308.0% | -166.8% | -239.4% | -161.2% | -132.3% | -110.6% | -128.4% | -96.1% | -78.5% | -31.4% | -103.7% | |
| Net Margin | -341.5% | -201.2% | -153.0% | -244.9% | -138.8% | 37.3% | -92.6% | -130.4% | -98.6% | -82.0% | -34.2% | -109.2% | |
| Pretax Margin | -341.3% | -201.0% | -158.7% | -244.9% | -210.6% | · | · | · | · | · | · | · | |
| EBITDA Margin | -346.1% | -308.0% | -166.8% | -239.4% | -161.2% | -132.3% | -110.6% | -119.3% | -87.0% | -74.3% | -27.4% | -96.8% | |
| ROA | -53.4% | -20.6% | -17.5% | -16.7% | -15.0% | 10.5% | -52.9% | -65.2% | -65.4% | -55.3% | -24.8% | -50.7% | |
| ROE | -1634.9% | -64.6% | -41.9% | -52.8% | -22.2% | 12.7% | -158.8% | -83.4% | -108.0% | -94.0% | -49.3% | -106.6% | |
| ROIC | -10360.5% | -93.7% | -46.0% | · | -17.5% | · | · | · | · | · | · | · |
Likidite ve Solventlik
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.1 | 7.5 | 7.8 | 3.2 | 15.4 | 9.2 | 1.6 | 4.9 | 3.5 | 3.2 | 2.9 | 3.7 | |
| Quick Ratio | 4.3 | 6.3 | 7.0 | 3.0 | 14.9 | 8.7 | 1.3 | 4.1 | 2.7 | 2.5 | 2.3 | 3.3 | |
| Debt / Equity | · | 0.0 | 0.0 | 0.0 | 0.0 | · | 0.3 | · | · | · | · | · | |
| Interest Coverage | · | · | -23.3 | -20.9 | -16.8 | -391.0 | -38.5 | -41.7 | -30.7 | -22.0 | -10.0 | -22.2 |
Verimlilik
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.2 | 0.1 | 0.1 | 0.1 | 0.1 | 0.3 | 0.6 | 0.5 | 0.7 | 0.7 | 0.7 | 0.5 | |
| Inventory Turnover | 2.1 | 2.0 | 2.8 | 2.1 | 3.7 | 3.4 | 3.6 | 2.6 | 3.0 | 3.5 | 3.5 | 3.5 | |
| Receivables Turnover | 5.1 | 4.8 | 7.2 | 6.0 | 6.4 | 4.9 | 7.6 | 7.1 | 7.5 | 10.9 | 21.4 | 19.7 |
Hisse Başına
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $0.02 | $1.72 | $2.62 | $2.49 | $3.58 | $1.74 | $0.36 | $0.76 | $0.74 | $0.91 | $0.92 | $0.74 | |
| Revenue / Share | $0.53 | $0.53 | $0.79 | $0.57 | $0.64 | $0.45 | · | · | · | · | · | · | |
| Cash Flow / Share | $-0.37 | $-0.71 | $-1.02 | $-1.17 | $-0.54 | $0.11 | · | · | · | · | · | · | |
| Cash / Share | $0.21 | $0.19 | $0.67 | $1.44 | $2.08 | $0.42 | $0.19 | $0.13 | $0.14 | $0.18 | $0.42 | $0.49 | |
| Dividend / Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| EPS (TTM) | $-1.82 | $-1.59 | $-1.21 | $-1.40 | $-0.89 | $0.17 | $-0.55 | $-0.76 | · | · | · | · |
Büyüme Oranları
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 3.9% | -23.2% | 56.3% | -1.7% | 65.4% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 7.6% | 5.7% | 36.5% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 15.2% | · | · | · | · | · | · | · | · | · | · | · |
Değerleme (TTM)
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $160M | $154M | $201M | $128M | $131M | $79M | $91M | $79M | $93M | $91M | $93M | $61M | |
| Net Income TTM | $-546M | $-310M | $-307M | $-314M | $-181M | $29M | $-84M | $-103M | $-92M | $-74M | $-32M | $-66M | |
| Market Cap | $565M | $539M | $2.63B | $1.85B | $4.52B | $4.99B | $787M | $1.11B | $307M | $352M | $1.05B | $580M | |
| Enterprise Value | · | $149M | $2.00B | $1.08B | $3.48B | · | $754M | · | · | · | · | · | |
| P/E | -1.0 | -1.2 | -8.1 | -5.8 | -23.0 | 152.6 | -9.3 | -9.7 | · | · | · | · | |
| P/S | 3.5 | 3.5 | 13.1 | 14.4 | 34.6 | 63.2 | 8.7 | 14.1 | 3.3 | 3.9 | 11.3 | 9.6 | |
| P/B | 105.6 | 1.1 | 3.7 | 3.3 | 5.7 | 14.9 | 14.3 | 9.7 | 3.6 | 4.2 | 14.3 | 10.5 | |
| P / Tangible Book | · | · | · | · | · | 14.9 | · | · | · | · | · | · | |
| P / Cash Flow | -5.1 | -2.6 | -10.1 | -7.0 | -40.7 | 255.8 | -10.0 | -16.7 | -4.5 | -5.2 | -21.9 | -11.3 | |
| P / FCF | -5.0 | -2.5 | -9.8 | -6.6 | -38.6 | 270.2 | -9.7 | -16.3 | -3.9 | -4.6 | -20.6 | -10.9 | |
| EV / EBITDA | · | -0.3 | -6.0 | -3.5 | -16.5 | · | -7.5 | · | · | · | · | · | |
| EV / FCF | · | -0.7 | -7.4 | -3.9 | -29.7 | · | -9.3 | · | · | · | · | · | |
| EV / Revenue | · | 1.0 | 10.0 | 8.4 | 26.7 | · | 8.3 | · | · | · | · | · | |
| Earnings Yield | -97.3% | -86.9% | -12.3% | -17.1% | -4.3% | 0.66% | -10.7% | -10.3% | · | · | · | · |
Gelir Tablosu
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $39M | $37M | $45M | $38M | $40M | $37M | $39M | $40M | $36M | $39M | $58M | $56M | $48M | $39M | $27M | $32M | |
| Cost of Revenue | $26M | $24M | $28M | $23M | $25M | $39M | $29M | $30M | $30M | $28M | $49M | $38M | $32M | $29M | $22M | $19M | |
| Gross Profit | $13M | $13M | $17M | $16M | $15M | $-1M | $10M | $10M | $6M | $11M | $10M | $18M | $16M | $10M | $5M | $14M | |
| R&D Expense | $23M | $20M | $23M | $23M | $23M | $29M | $27M | $26M | $38M | $43M | $45M | $48M | $46M | $49M | $43M | $47M | |
| SG&A Expense | $33M | $31M | $34M | $31M | $36M | $40M | $42M | $44M | $46M | $44M | $46M | $43M | $41M | $40M | $45M | $37M | |
| Operating Expenses | $57M | $21M | $58M | $55M | $60M | $428M | $163M | $74M | $182M | $93M | $97M | $100M | $89M | $101M | $92M | $88M | |
| Operating Income | $-45M | $-8M | $-41M | $-39M | $-45M | $-429M | $-153M | $-64M | $-176M | $-81M | $-88M | $-82M | $-73M | $-91M | $-87M | $-75M | |
| Interest Expense | · | · | · | · | · | · | · | · | · | $4M | · | $4M | $4M | $4M | · | $4M | |
| Other Non-op | $2M | $2M | $3M | $3M | $5M | $4M | $4M | $7M | $6M | $7M | $8M | $9M | $9M | $7M | $6M | $1M | |
| Pretax Income | $-45M | $-8M | $-40M | $-38M | $-42M | $-426M | $3M | $-61M | $-173M | $-78M | $-83M | $-78M | $-70M | $-88M | $-84M | $-77M | |
| Income Tax | $58.0K | $184.0K | $202.0K | $383.0K | $35.0K | $-302.0K | $316.0K | $0 | $0 | $0 | $-718.0K | $-11M | $0 | $0 | $0 | $0 | |
| Net Income | $-45M | $-8M | $-40M | $-38M | $-42M | $-426M | $2M | $-61M | $-173M | $-78M | $-82M | $-67M | $-70M | $-88M | $-84M | $-77M | |
| EPS (Basic) | $-0.14 | $-0.03 | $-0.11 | $-0.13 | $-0.14 | $-1.44 | $0.02 | $-0.22 | $-0.64 | $-0.29 | $-0.31 | $-0.26 | $-0.28 | $-0.36 | $-0.37 | $-0.34 | |
| EPS (Diluted) | $-0.14 | $-0.03 | $-0.11 | $-0.13 | $-0.14 | $-1.44 | $-0.44 | $-0.22 | $-0.64 | $-0.29 | $-0.31 | $-0.26 | $-0.28 | $-0.36 | $-0.37 | $-0.34 | |
| Shares (Basic) | 310,655,000 | 305,819,000 | · | 300,844,000 | 300,162,000 | 296,858,000 | · | 272,915,000 | 272,385,000 | 269,578,000 | · | 255,001,000 | 250,070,000 | 242,032,000 | · | 225,123,000 | |
| Shares (Diluted) | 310,655,000 | 305,819,000 | · | 300,844,000 | 300,162,000 | 296,858,000 | · | 272,915,000 | 272,385,000 | 269,578,000 | · | 255,001,000 | 250,070,000 | 242,032,000 | · | 225,123,000 | |
| EBITDA | $-45M | $-8M | · | $-39M | $-45M | $-429M | · | $-64M | $-176M | $-81M | · | $-82M | $-73M | $-91M | · | $-75M |
Bilanço
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $61M | $56M | $64M | $56M | $55M | $59M | $55M | $78M | $100M | $77M | $180M | $386M | $209M | $354M | $325M | $304M | |
| Short-term Investments | $176M | $220M | $216M | $242M | $260M | $285M | $335M | $393M | $410M | $485M | · | $382M | $621M | $521M | · | $530M | |
| Receivables | $31M | $29M | $35M | $31M | $32M | $32M | $28M | $29M | $32M | $30M | · | $30M | $24M | $30M | · | $23M | |
| Inventory | $61M | $51M | $49M | $53M | $54M | $54M | $59M | $66M | $69M | $67M | · | $68M | $68M | $62M | · | $43M | |
| Prepaid Expense | $10M | $13M | $11M | $12M | $12M | $15M | $19M | $17M | $17M | $17M | · | $15M | $14M | $14M | · | $13M | |
| Current Assets | $339M | $370M | $375M | $394M | $413M | $445M | $496M | $584M | $628M | $677M | · | $882M | $936M | $981M | · | $914M | |
| PP&E (Net) | $27M | $24M | $24M | $22M | $23M | $25M | $31M | $32M | $35M | $37M | · | $40M | $40M | $41M | · | $39M | |
| PP&E (Gross) | · | · | $117M | · | · | · | $112M | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $92M | · | · | · | $82M | · | · | · | · | · | · | · | · | · | |
| Goodwill | $318M | $318M | $318M | $318M | $318M | $318M | $318M | $369M | $369M | $462M | · | $464M | $410M | $410M | · | $410M | |
| Intangibles | $13M | $14M | $15M | $16M | $17M | $18M | $390M | $436M | $443M | $450M | · | $462M | $410M | $410M | · | $410M | |
| Other Non-current Assets | $13M | $14M | $9M | $9M | $9M | $9M | $9M | $10M | $10M | $10M | · | $13M | $13M | $13M | · | $1M | |
| Total Assets | $752M | $782M | $784M | $803M | $825M | $861M | $1.26B | $1.45B | $1.51B | $1.67B | · | $1.90B | $1.85B | $1.90B | · | $1.82B | |
| Accounts Payable | $19M | $14M | $21M | $16M | $15M | $14M | $17M | $12M | $17M | $21M | · | $16M | $17M | $17M | · | $13M | |
| Accrued Liabilities | $30M | $34M | $34M | $29M | $27M | $29M | $23M | $19M | $22M | $22M | · | $35M | $27M | $19M | · | $25M | |
| Current Liabilities | $69M | $65M | $73M | $63M | $60M | $67M | $66M | $60M | $78M | $73M | · | $184M | $271M | $266M | · | $82M | |
| Capital Leases | $60M | $59M | $57M | $54M | $52M | $50M | $15M | $17M | $20M | $29M | · | $34M | $37M | $39M | · | $43M | |
| Other Non-current Liabilities | $8M | $8M | $0 | $0 | $0 | $0 | $546.0K | $751.0K | $751.0K | $751.0K | · | $1M | $837.0K | $969.0K | · | $2M | |
| Total Liabilities | $785M | $780M | $779M | $767M | $764M | $769M | $754M | $997M | $1.02B | $1.02B | · | $1.13B | $1.21B | $1.20B | · | $1.19B | |
| Long-term Debt | · | · | · | · | · | · | · | · | · | · | · | · | · | $897M | · | $897M | |
| Common Stock | $311.0K | $311.0K | $302.0K | $302.0K | $300.0K | $300.0K | $294.0K | $274.0K | $272.0K | $272.0K | · | $258.0K | $250.0K | $250.0K | · | $226.0K | |
| Paid-in Capital | $2.72B | $2.71B | $2.70B | $2.69B | $2.68B | $2.67B | $2.65B | $2.60B | $2.58B | $2.57B | · | $2.52B | $2.33B | $2.31B | · | $2.08B | |
| Retained Earnings | $-2.75B | $-2.70B | $-2.70B | $-2.65B | $-2.62B | $-2.58B | $-2.15B | $-2.15B | $-2.09B | $-1.92B | · | $-1.76B | $-1.69B | $-1.62B | · | $-1.45B | |
| AOCI | $-503.0K | $-147.0K | $457.0K | $415.0K | $267.0K | $381.0K | $422.0K | $2M | $-523.0K | $-306.0K | · | $-2M | $-3M | $-2M | · | $-6M | |
| Stockholders' Equity | $-33M | $2M | $5M | $36M | $61M | $92M | $507M | $453M | $493M | $649M | $701M | $764M | $642M | $692M | $563M | $627M | |
| Liabilities + Equity | $752M | $782M | $784M | $803M | $825M | $861M | $1.26B | $1.45B | $1.51B | $1.67B | · | $1.90B | $1.85B | $1.90B | · | $1.82B | |
| Shares Outstanding | 310,810,000 | 310,487,000 | 301,956,000 | 301,853,000 | 300,350,000 | 300,041,000 | 294,418,000 | 273,812,000 | 272,491,000 | 272,280,000 | 267,744,000 | 258,374,000 | 250,473,000 | 249,803,000 | 226,505,000 | 225,916,000 |
Nakit Akışı
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $9M | $4M | $10M | $11M | $12M | $9M | $16M | $18M | $17M | $20M | $17M | $20M | $18M | $18M | $18M | $19M | |
| Amort. of Intangibles | · | $1M | $1M | $1M | $1M | $366M | $7M | $7M | $7M | $7M | $7M | $942.0K | $232.0K | $234.0K | $228.0K | $229.0K | |
| Restructuring | · | · | · | · | · | · | · | · | $11M | · | · | · | · | · | · | · | |
| Operating Cash Flow | $-36M | $-45M | $-19M | $-19M | $-29M | $-44M | $-31M | $-45M | $-54M | $-76M | $-58M | $-65M | $-42M | $-95M | $-61M | $-63M | |
| CapEx | $2M | $3M | $861.0K | $-86.0K | $550.0K | $1M | $2M | $-787.0K | $1M | $4M | $2M | $830.0K | $2M | $4M | $5M | $4M | |
| Investing Cash Flow | $40M | $36M | $26M | $19M | $25M | $45M | $58M | $23M | $77M | $-34M | $-67M | $242M | $-99M | $-73M | $80M | $54M | |
| Stock Issued | · | · | · | · | · | · | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $189M | $0 | $-6M | |
| Net Stock Activity | · | · | · | · | · | · | · | · | · | $0 | · | · | · | $189M | · | · | |
| Financing Cash Flow | $255.0K | $1M | $0 | $1M | $0 | $2M | $-50M | $812.0K | $-152.0K | $7M | $-82M | $-781.0K | $-5M | $196M | $819.0K | $3M | |
| Net Change in Cash | $5M | $-7M | $7M | $2M | $-4M | $3M | $-23M | $-22M | $22M | $-103M | $-206M | $176M | $-145M | $29M | $21M | $-6M | |
| Free Cash Flow | · | $-48M | · | · | · | $-45M | · | · | · | $-80M | · | · | · | $-98M | · | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | $-83M | · | · | · | $-102M | · | · |
Kârlılık
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 32.4% | 34.5% | · | 41.4% | 36.9% | -3.7% | · | 25.0% | 16.5% | 29.1% | · | 32.1% | 32.7% | 25.1% | · | 41.9% | |
| Operating Margin | -114.4% | -22.5% | · | -101.1% | -112.8% | -1154.5% | · | -160.3% | -488.3% | -209.6% | · | -148.1% | -153.8% | -234.6% | · | -230.9% | |
| Net Margin | -114.7% | -22.3% | · | -98.9% | -105.4% | -1146.8% | · | -151.9% | -481.3% | -201.4% | · | -120.1% | -146.8% | -226.3% | · | -238.2% | |
| Pretax Margin | -114.5% | -21.8% | · | -97.9% | -105.4% | -1147.6% | · | -151.9% | -481.3% | -201.4% | · | -139.3% | -146.8% | -226.3% | · | -238.2% | |
| EBITDA Margin | -114.4% | -22.5% | · | -101.1% | -112.8% | -1154.5% | · | -160.3% | -488.3% | -209.6% | · | -148.1% | -153.8% | -234.6% | · | -230.9% | |
| ROA | -5.7% | -1.0% | · | -3.4% | -3.6% | -33.7% | · | -3.6% | -10.3% | -4.4% | · | -3.6% | -3.8% | -4.6% | · | -4.0% | |
| ROE | -316.5% | -17.6% | · | -15.5% | -15.1% | -115.1% | · | -10.0% | -30.6% | -11.7% | · | -9.6% | -10.5% | -12.3% | · | -10.5% | |
| ROIC | 134.5% | -361.2% | · | -108.8% | -73.0% | -467.7% | · | -14.1% | -35.7% | -12.5% | · | -9.3% | -11.4% | -13.2% | · | · |
Likidite ve Solventlik
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.9 | 5.7 | · | 6.2 | 6.9 | 6.7 | · | 9.7 | 8.0 | 9.3 | · | 4.8 | 3.4 | 3.7 | · | 11.2 | |
| Quick Ratio | 3.9 | 4.7 | · | 5.2 | 5.8 | 5.6 | · | 8.3 | 6.9 | 8.1 | · | 4.3 | 3.1 | 3.4 | · | 10.5 | |
| Interest Coverage | · | · | · | · | · | · | · | · | · | -22.8 | · | -23.0 | -20.6 | -25.1 | · | -20.4 |
Verimlilik
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | |
| Inventory Turnover | 0.5 | 0.5 | · | 0.4 | 0.4 | 0.6 | · | 0.4 | 0.4 | 0.4 | · | 0.7 | 0.6 | 0.6 | · | 0.6 | |
| Receivables Turnover | 1.2 | 1.2 | · | 1.3 | 1.2 | 1.2 | · | 1.3 | 1.3 | 1.3 | · | 2.1 | 1.9 | 1.4 | · | 1.4 |
Hisse Başına
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $-0.11 | $0.01 | · | $0.12 | $0.20 | $0.31 | · | $1.65 | $1.81 | $2.38 | · | $2.96 | $2.56 | $2.77 | · | $2.77 | |
| Revenue / Share | $0.13 | $0.12 | · | $0.13 | $0.13 | $0.13 | · | $0.15 | $0.13 | $0.14 | · | $0.22 | $0.19 | $0.16 | · | $0.14 | |
| Cash Flow / Share | · | $-0.15 | · | · | · | $-0.15 | · | · | · | $-0.28 | · | · | · | $-0.39 | · | · | |
| Cash / Share | $0.20 | $0.18 | · | $0.19 | $0.18 | $0.20 | · | $0.28 | $0.37 | $0.28 | · | $1.49 | $0.84 | $1.42 | · | $1.35 | |
| EPS (TTM) | $-0.41 | $-0.41 | · | $-2.15 | $-2.24 | $-2.74 | · | $-1.46 | $-1.50 | $-1.14 | · | $-1.27 | $-1.35 | $-1.39 | · | $-1.34 |
Değerleme (TTM)
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $159M | $160M | · | $155M | $156M | $152M | · | $173M | $189M | $200M | · | $170M | $146M | $134M | · | $137M | |
| Net Income TTM | $-131M | $-129M | · | $-504M | $-526M | $-658M | · | $-394M | $-400M | $-297M | · | $-309M | $-319M | $-321M | · | $-299M | |
| Market Cap | $522M | $410M | · | $386M | $372M | $354M | · | $465M | $373M | $1.02B | · | $2.16B | $3.33B | $2.89B | · | $1.31B | |
| P/E | -4.1 | -3.2 | · | -0.6 | -0.6 | -0.4 | · | -1.2 | -0.9 | -3.3 | · | -6.6 | -9.9 | -8.3 | · | -4.3 | |
| P/S | 3.3 | 2.6 | · | 2.5 | 2.4 | 2.3 | · | 2.7 | 2.0 | 5.1 | · | 12.7 | 22.8 | 21.6 | · | 9.6 | |
| P/B | -15.7 | 173.2 | · | 10.7 | 6.1 | 3.9 | · | 1.0 | 0.8 | 1.6 | · | 2.8 | 5.2 | 4.2 | · | 2.1 | |
| P / Cash Flow | · | -9.2 | · | · | · | -8.0 | · | · | · | -13.5 | · | · | · | -30.5 | · | · | |
| Earnings Yield | -24.4% | -31.1% | · | -168.0% | -180.7% | -232.2% | · | -85.9% | -109.5% | -30.4% | · | -15.2% | -10.2% | -12.0% | · | -23.1% |
En son dönem solda · null değerler · olarak gösterilir
Finansal Tablolar Gelir tablosu, bilanço, nakit akışı — yıllık, son 5 yıl
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Gelir | $160M | $154M | $201M | $128M | $131M |
| Brüt Kâr Marjı % | 28.6% | 24.2% | 26.3% | 38.2% | 45.1% |
| Faaliyet Kâr Marjı % | -346.1% | -308.0% | -166.8% | -239.4% | -161.2% |
| Net Gelir | $-546M | $-310M | $-307M | $-314M | $-181M |
| Seyreltilmiş Hisse Başı Kâr | $-1.82 | $-1.59 | $-1.21 | $-1.40 | $-0.89 |
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Borç / Öz Sermaye | · | 0.0 | 0.0 | 0.0 | 0.0 |
| Cari Oran | 5.1 | 7.5 | 7.8 | 3.2 | 15.4 |
| Cari Oran | 4.3 | 6.3 | 7.0 | 3.0 | 14.9 |
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Serbest Nakit Akışı | $-114M | $-212M | $-268M | $-280M | $-117M |
Kurumsal Sahipler (13F) 244 dosya · $360.0M toplam · Tarih itibarıyla 30 Haziran 2026
Çeyreklik SEC Form 13F'lerinde bu hisse senedini tuttuklarını bildiren kurumlar. Yalnızca uzun pozisyonlar; tek bir başvuru sahibi, ayrı opsiyon bacakları için iki kez görünebilir. Büyük dengeleyici alım/satım bacakları genellikle piyasa yapımını veya korunmuş envanteri yansıtır, yönlü bir inancı değil.
Sahipler
244
Tutulan Değer
$360.0M
Yeni pozisyonlar
24
Çıkan pozisyonlar
28
Kurumsal faaliyet — Q2 2026 ve önceki çeyrek
| Yeni pozisyonlar | Çıkan pozisyonlar | Artırıldı | Azaldı | Net hisse senedi değişimi |
|---|---|---|---|---|
| 24 (-30 önceki Ç'ye göre) | 28 (-2 önceki Ç'ye göre) | 72 (+14 önceki Ç'ye göre) | 80 (+4 önceki Ç'ye göre) | +4.3M |
Q1 2026 ile karşılaştırıldı. SEC Form 13F başvuruları, çeyrek sonundan itibaren 45 gün içinde ve geç başvuranlar için kısa bir ek süre içinde tamamlanmalıdır — bu pencere içindeki çeyrekler, en son tam olarak raporlanan çifte tercih edilerek atlanır.
| Kurum | Değer | Hisse senetleri | % izlenen 13F'nin | Tür |
|---|---|---|---|---|
| BlackRock, Inc. | $54.330.444 | 32.339.550 | 15,09% | Hisse senetleri |
| ARK Investment Management LLC | $50.032.778 | 29.781.416 | 13,90% | Hisse senetleri |
| SOFTBANK GROUP CORP. | $34.358.638 | 20.451.570 | 9,54% | Hisse senetleri |
| VANGUARD GROUP INC | $31.859.776 | 17.037.314 | 8,85% | Hisse senetleri |
| VANGUARD CAPITAL MANAGEMENT LLC | $22.508.529 | 13.397.934 | 6,25% | Hisse senetleri |
| GEODE CAPITAL MANAGEMENT, LLC | $12.782.429 | 7.606.518 | 3,55% | Hisse senetleri |
| Sumitomo Mitsui Trust Group, Inc. | $10.096.321 | 6.009.715 | 2,80% | Hisse senetleri |
| Amova Asset Management Americas, Inc. | $10.036.224 | 6.009.715 | 2,79% | Hisse senetleri |
| STATE STREET CORP | $10.014.774 | 5.961.175 | 2,78% | Hisse senetleri |
| Point72 Asset Management, L.P. | $8.042.664 | 4.787.300 | 2,23% | Hisse senetleri |
| TWO SIGMA INVESTMENTS, LP | $7.127.566 | 4.242.599 | 1,98% | Hisse senetleri |
| D. E. Shaw & Co., Inc. | $7.069.686 | 4.208.146 | 1,96% | Hisse senetleri |
| MILLENNIUM MANAGEMENT LLC | $6.656.903 | 3.962.442 | 1,85% | Hisse senetleri |
| Point72 (DIFC) Ltd | $5.465.775 | 4.270.137 | 1,52% | Hisse senetleri |
| GOLDMAN SACHS GROUP INC | $5.426.210 | 3.229.887 | 1,51% | Hisse senetleri |
| CITADEL ADVISORS LLC | $4.781.117 | 2.845.903 | 1,33% | Hisse senetleri |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $4.488.819 | 2.671.916 | 1,25% | Hisse senetleri |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $4.455.861 | 2.652.298 | 1,24% | Hisse senetleri |
| NORTHERN TRUST CORP | $3.952.681 | 2.352.786 | 1,10% | Hisse senetleri |
| VANGUARD FIDUCIARY TRUST CO | $3.675.213 | 2.187.627 | 1,02% | Hisse senetleri |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $3.577.162 | 2.129.263 | 0,99% | Hisse senetleri |
| Longaeva Partners L.P. | $3.558.628 | 2.118.231 | 0,99% | Hisse senetleri |
| IQ EQ FUND MANAGEMENT (IRELAND) Ltd | $2.846.837 | 1.694.546 | 0,79% | Hisse senetleri |
| Birchview Capital, LP | $2.268.000 | 1.350.000 | 0,63% | Hisse senetleri |
| BANK OF AMERICA CORP /DE/ | $2.264.860 | 1.348.131 | 0,63% | Hisse senetleri |
| Invesco Ltd. | $2.179.114 | 1.297.091 | 0,61% | Hisse senetleri |
| AQR CAPITAL MANAGEMENT LLC | $2.178.430 | 1.296.684 | 0,61% | Hisse senetleri |
| Nuveen, LLC | $1.718.830 | 1.023.113 | 0,48% | Hisse senetleri |
| RENAISSANCE TECHNOLOGIES LLC | $1.623.216 | 966.200 | 0,45% | Hisse senetleri |
| BOURNE LENT ASSET MANAGEMENT INC | $1.584.332 | 943.055 | 0,44% | Hisse senetleri |
| TWO SIGMA ADVISERS, LP | $1.547.425 | 827.500 | 0,43% | Hisse senetleri |
| HHLR ADVISORS, LTD. | $1.543.739 | 918.892 | 0,43% | Hisse senetleri |
| UBS Group AG | $1.500.475 | 893.140 | 0,42% | Hisse senetleri |
| Universal- Beteiligungs- und Servicegesellschaft mbH | $1.358.616 | 808.700 | 0,38% | Hisse senetleri |
| Bank of New York Mellon Corp | $1.289.512 | 767.567 | 0,36% | Hisse senetleri |
| DIMENSIONAL FUND ADVISORS LP | $1.277.135 | 759.783 | 0,35% | Hisse senetleri |
| Casdin Capital, LLC | $1.215.929 | 723.767 | 0,34% | Hisse senetleri |
| TUDOR INVESTMENT CORP ET AL | $1.150.308 | 684.707 | 0,32% | Hisse senetleri |
| XTX Topco Ltd | $1.073.322 | 638.882 | 0,30% | Hisse senetleri |
| Numerai GP LLC | $1.044.068 | 621.469 | 0,29% | Hisse senetleri |
| CARRET ASSET MANAGEMENT, LLC | $1.008.235 | 600.140 | 0,28% | Hisse senetleri |
| Man Group plc | $1.003.521 | 597.334 | 0,28% | Hisse senetleri |
| Russell Investments Group, Ltd. | $1.002.694 | 596.843 | 0,28% | Hisse senetleri |
| Balyasny Asset Management L.P. | $948.090 | 564.339 | 0,26% | Hisse senetleri |
| PEAK6 LLC | $933.327 | 555.552 | 0,26% | Hisse senetleri |
| Vestmark Advisory Solutions, Inc. | $803.384 | 478.205 | 0,22% | Hisse senetleri |
| MORGAN STANLEY | $802.664 | 477.776 | 0,22% | Hisse senetleri |
| ArrowMark Colorado Holdings LLC | $786.882 | 468.382 | 0,22% | Hisse senetleri |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | $741.954 | 441.639 | 0,21% | Hisse senetleri |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $673.008 | 400.600 | 0,19% | Satım opsiyonu |
Aktivistler ve %5+ sahipler 1 pozisyon
SEC Çizelge 13D dosyalayan yatırımcılar — ihraççı üzerinde nüfuz etme niyetiyle %5'in üzerinde faydalı sahiplik (aktivist hisseler, yönetim kurulu kampanyaları, M&A). Her satır, o başvuru sahibinin pozisyonunun bilinen en son durumunu gösterir.
| Başvuru sahibi | Dosyalandı | Hisse | Durum | Amaç | Başvuru |
|---|---|---|---|---|---|
| Magnetar Financial LLC, Magnetar Capital Partners LP, Supernova Management LLC, Alec N. Litowitz ×3 başvurular | 29 Ağustos 2019 | · | İlk başvuru | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Şirket yöneticileri 30 içeriden öğrenenler · 6 yöneticiler · 11 yönetim kurulu üyeleri
| İçeriden Öğrenen | Rol | Son işlem | Sahip olunan hisse senetleri | Alımlar 12ay | Satışlar 12ay | Net 12ay |
|---|---|---|---|---|---|---|
| Mark Van Oene | President & CEO | 17 Ağustos 2026 S | 2.705.853 | 0 | 4 | $-335.122 |
| Susan K Barnes | EVP, CFO and PAO | 19 Şubat 2020 S | 874.812 | 0 | 0 | $0 |
| James Michael Phillips | SVP, Research & Development | 24 Mart 2020 S | 249.220 | 0 | 0 | $0 |
| Kevin P Corcoran | SVP, Market Development | 24 Kasım 2017 M | 158.174 | 0 | 0 | $0 |
| Michael Glynn | Chief Commercial Officer | 15 Şubat 2012 A | · | 0 | 0 | $0 |
| Stephen W Turner | VP & Chief Technology Officer | 11 Temmuz 2011 J | 1.093.063 | 0 | 0 | $0 |
| Christopher Gibson | Yönetim kurulu üyesi | 03 Haziran 2026 A | 111.386 | 0 | 0 | $0 |
| Hannah Valantine | Yönetim kurulu üyesi | 03 Haziran 2026 A | 22.821 | 0 | 0 | $0 |
| William W. Ericson | Yönetim kurulu üyesi | 03 Haziran 2026 A | 41.616 | 0 | 0 | $0 |
| Christopher M Smith | Yönetim kurulu üyesi | 03 Haziran 2026 A | 54.099 | 0 | 0 | $0 |
| Marshall Mohr | Yönetim kurulu üyesi | 03 Haziran 2026 A | 132.821 | 0 | 0 | $0 |
| Randall S Livingston | Yönetim kurulu üyesi | 03 Haziran 2026 A | 22.821 | 0 | 0 | $0 |
| Kathy Ordonez | Yönetim kurulu üyesi | 03 Haziran 2026 A | 403.037 | 0 | 0 | $0 |
| John F Milligan | Yönetim kurulu üyesi | 03 Haziran 2026 A | 132.821 | 0 | 0 | $0 |
| David B. Singer | Yönetim kurulu üyesi | 13 Haziran 2012 A | · | 0 | 0 | $0 |
| Susan E Siegel | Yönetim kurulu üyesi | 13 Haziran 2012 A | 65.000 | 0 | 0 | $0 |
| Hugh C Martin | Yönetim kurulu üyesi | 03 Şubat 2012 M | 342.458 | 0 | 0 | $0 |
| James R Gibson II | · | 01 Nisan 2026 S | 1.245.663 | 0 | 1 | $-120.813 |
| Michele Farmer | · | 03 Mart 2026 S | 305.948 | 0 | 3 | $-84.510 |
| Christian O Henry | · | 03 Mart 2026 S | 3.581.813 | 0 | 3 | $-772.728 |
| Lucy Shapiro | · | 04 Haziran 2025 A | 22.821 | 0 | 0 | $0 |
| Susan G. Kim | · | 30 Eylül 2024 S | 695.654 | 0 | 0 | $0 |
| Jeff Eidel | · | 19 Ağustos 2024 S | 869.730 | 0 | 0 | $0 |
| David W Meline | · | 18 Haziran 2024 A | 57.116 | 0 | 0 | $0 |
| David Botstein | · | 24 Mayıs 2023 A | 0 | 0 | 0 | $0 |
| Peter Fromen | · | 02 Mart 2022 A | 190.280 | 0 | 0 | $0 |
| Michael Hunkapiller | · | 26 Şubat 2021 M | 848.405 | 0 | 0 | $0 |
| Eric Schaefer | · | 22 Şubat 2021 S | 88.474 | 0 | 0 | $0 |
| BYERS BROOK H | · | 17 Mayıs 2016 A | 110.504 | 0 | 0 | $0 |
| Brian B Dow | · | 02 Mart 2015 P | 18.119 | 0 | 0 | $0 |
SEC Form 3/4/5 başvurularından yöneticiler; net = yalnızca açık piyasa Alış/Satış
ETF sahipliği 21 ETF'ler tarafından tutuluyor
Ağırlık yalnızca doğrudan öz sermaye varlıklarını (N-PORT) yansıtır; kaldıraçlı veya türev tabanlı fonlar gösterilmeyen ek swap pozisyonlarına sahip olabilir.
| Fon | Ağırlık | Birimler | Tarih itibarıyla | Kaynak |
|---|---|---|---|---|
| ARKG · ARK ETF Trust | 0,96% | 10.630.263 NS | 31 Temmuz 2026 | N-PORT |
| QQQS · Invesco Exchange-Traded Fund Trust … | 0,91% | 88.548 SH | 01 Ekim 2026 | Günlük |
| IDNA · iShares Trust | 0,35% | 711.655 SH | 11 Eylül 2026 | Günlük |
| ARKK · ARK ETF Trust | 0,32% | 12.810.378 NS | 31 Temmuz 2026 | N-PORT |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,09% | 1.001.721 SH | 01 Ekim 2026 | Günlük |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,05% | 21.993 SH | 01 Ekim 2026 | Günlük |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,03% | 280.941 SH | 19 Ağustos 2026 | Günlük |
| IBB · iShares Trust | 0,03% | 2.192.352 SH | 11 Eylül 2026 | Günlük |
| IWO · iShares Trust | 0,02% | 2.473.318 SH | 11 Eylül 2026 | Günlük |
| RSSL · Global X Funds | 0,01% | 134.834 NS | 31 Temmuz 2026 | N-PORT |
| IWM · iShares Trust | 0,01% | 7.217.251 SH | 11 Eylül 2026 | Günlük |
| VXF · VANGUARD INDEX FUNDS | 0,01% | 3.579.782 SH | 19 Ağustos 2026 | Günlük |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,01% | 1.624.029 SH | 19 Ağustos 2026 | Günlük |
| VHT · VANGUARD WORLD FUND | 0,01% | 727.094 SH | 19 Ağustos 2026 | Günlük |
| ITOT · iShares Trust | 0,00% | 431.328 SH | 11 Eylül 2026 | Günlük |
| IWV · iShares Trust | 0,00% | 69.680 SH | 09 Eylül 2026 | Günlük |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 9.535.565 SH | 19 Ağustos 2026 | Günlük |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0,00% | 17.047 SH | 19 Ağustos 2026 | Günlük |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 22.805 SH | 19 Ağustos 2026 | Günlük |
| DFAC · Dimensional ETF Trust | 0,00% | 8.144 NS | 31 Temmuz 2026 | N-PORT |
| IWN · iShares Trust | · | 207.024 SH | 11 Eylül 2026 | Günlük |
PACB Analist Uzlaşması Boğa ve ayı analist görüşleri, 12 aylık fiyat hedefi, yukarı yönlü potansiyel
derecelendirme · 14 analist
AL
Medyan hedef
$2.00
-21,3%
4 28,6%
Güçlü Al
5 35,7%
Al
4 28,6%
Tut
1 7,1%
Sat
0 0,0%
Güçlü Sat
12 Aylık Fiyat Hedefi
7 analist · 2026-10-02Ortalama hedef $2.16 -15,1%
Şimdi
Mevcut fiyat $2.54
Düşük$1.25
Ortalama$2.16
Yüksek$3.00
Akran karşılaştırması (GICS alt sektörü) Anahtar metrikler sektördeki benzerlerine karşı
Mali yıl bazında, fiyatlar her şirketin son mali yıl kapanışına göredir.
| Hisse Sembolü | Piyasa Değeri | P/E | Gelir YoY | Net Kar Marjı | ROE | Brüt Kar Marjı |
|---|---|---|---|---|---|---|
| PACB | $565M | -1.0 | 3.9% | -341.5% | -1634.9% | 28.6% |
| BLFS | · | -241.8 | 28.9% | · | · | · |
| PSNL | $816M | -8.7 | -17.7% | -116.7% | -36.0% | · |
| AZTA | $1.32B | -23.5 | 3.5% | -9.4% | -3.3% | 45.5% |
| CYRX | $479M | 6.9 | 12.4% | 44.4% | 15.3% | 47.1% |
| DNA | $484M | -1.5 | -25.1% | -183.8% | -55.8% | · |
| CTKB | $649M | 505.0 | 0.52% | -33.0% | -18.5% | 51.8% |
| MLAB | $489M | 73.1 | 3.4% | 2.7% | 3.7% | 63.5% |
| OABI | · | · | · | · | · | · |
| TKNO | $204M | -11.9 | 7.3% | -42.6% | -23.8% | 33.2% |
| QSI | · | · | · | · | · | · |
Metriklerim Kişisel izleme listeniz — Tam Temeller'den seçilen satırlar
Sizin için önemli olan metrikleri seçin — Yukarıdaki Tam Temeller bölümündeki herhangi bir satırın yanındaki + işaretine tıklayın.
Seçiminiz kaydedildi ve tüm hisse senetlerinde sizinle birlikte gelir.
Kaynak: SEC 10-Q dosyalandı Ağu 6, 2026